PolyPeptide Group AG PPGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PPGN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CHF 33.55
- Day Range
- CHF 33.00–33.90
- 52-Week Range
- CHF 14.11–34.60
- Bid/Ask
- CHF 33.00 / CHF 34.45
- Market Cap
- CHF 1.09 Bil
- Volume/Avg
- 29,966 / 63,324
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,273
- Website
- https://www.polypeptide.com
Comparables
Valuation
|
Metric
|
PPGN
|
DESN
|
SFZN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 40.88 | 24.05 |
Price/Book Value | 3.13 | — | 4.96 |
Price/Sales | 3.55 | 10.52 | 3.00 |
Price/Cash Flow | — | 31.09 | 17.25 |
Price/Earnings
PPGN
DESN
SFZN
Financial Strength
|
Metric
|
PPGN
|
DESN
|
SFZN
|
|---|---|---|---|
Quick Ratio | 1.09 | 1.65 | 1.35 |
Current Ratio | 1.85 | 2.56 | 2.47 |
Interest Coverage | −9.37 | 56.42 | 17.11 |
Quick Ratio
PPGN
DESN
SFZN
Profitability
|
Metric
|
PPGN
|
DESN
|
SFZN
|
|---|---|---|---|
Return on Assets (Normalized) | −6.13% | 8.08% | 7.09% |
Return on Equity (Normalized) | −9.58% | 10.81% | 17.53% |
Return on Invested Capital (Normalized) | −7.07% | 10.12% | 10.47% |
Return on Assets
PPGN
DESN
SFZN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Llzmsytw | Qpxg | $79.1 Bil | |
MKKGY
| Merck KGaA ADR | Pbpcbkmny | Wyxqxqt | $74.3 Bil | |
HLN
| Haleon PLC ADR | Jrjcqmmk | Kbx | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xnmqlqz | Dzlx | $19.1 Bil | |
VTRS
| Viatris Inc | Fljztbx | Wbtcy | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Xfwfprdr | Rsf | $11.7 Bil | |
CTLT
| Catalent Inc | Jnkqlnnwc | Qblxpfr | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Shbjbmmt | Nlwj | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Txyrlyyk | Jnbw | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qgsjvlgnj | Zztxff | $3.3 Bil |